



Editorial

Metabolic profiling—multitude of technologies with great research potential, but (when) will translation emerge?

Mika Ala-Korpela^{1,2*} and George Davey Smith²

¹Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland and ²Medical Research Council Integrative Epidemiology Unit and School of Social and Community Medicine, University of Bristol, Bristol, UK

*Corresponding author. Computational Medicine, Faculty of Medicine, P.O. Box 5000 FI-90014 University of Oulu, Oulu, Finland. E-mail: mika.ala-korpela@computationalmedicine.fi

Metabolic phenotyping, nowadays most often termed ‘metabolomics’, is becoming increasingly applied in molecular epidemiology, particularly in concert with genomics. Since Jeremy Nicholson and colleagues coined the term ‘metabonomics’ in 1999,¹ over 15 000 publications have appeared under this conceptual and technological umbrella (a Pubmed search on 15 August 2016 at [<http://www.ncbi.nlm.nih.gov/pubmed/>] with metabonomics or metabolomics or lipidomics). Most of the published works have been, and still continue to be, methodologically oriented² and thereby bear little direct relevance to applied epidemiology. Particularly the spectroscopy-based chemometric approaches—typically aiming at classification of individuals with or without a particular disease—have for a long time (mis)guided metabolomics research.^{3–9} Many of the limitations of these types of multivariate metabolomics applications are currently well understood: overtraining of classification models with high numbers of variables (typically spectral data points), cross-sectional study settings with very small numbers of individuals and no independent replication.^{5,7,8} However, some lack of clarity still remains, partly related to some misplaced conceptions as to the scope of truly personalized medicine.^{10–13} Individual diagnostics of polygenic diseases, when both the disease liability¹⁴ and the metabolic phenotypes^{15–17} are continuous, fundamentally preclude diagnostic models that would provide both high sensitivity and high specificity.^{4,5,7,18–20} For example, conditions like autism, long considered rigid

disease classifications, clearly involve a somewhat arbitrary division of a continuously distributed underlying liability,²¹ limiting attempts at improved binary classification. In addition, many metabolomics applications have ignored confounding in data analyses and interpretations, though it is well established in observational epidemiology that confounding—by lifestyle and socioeconomic factors, or by baseline health status, treatment and medication effects—is prone to affect many associations.^{22,23}

Getting quantitative and molecular

Recent technological developments resulting in increased numbers of quantitative molecular applications of metabolomics triggered the idea for this themed issue in metabolic phenotyping in epidemiology. The pivotal role of absolute quantification of identified molecular entities in epidemiology and genetics is evident from a multitude of recent applications.^{6,24–28} The data analysis protocols in mass spectrometry (MS) often build on a quantitative logic, i.e. identification, assignment and evaluation of specific molecular signals. Though most of the MS-based studies have been small or moderate in numbers from the epidemiological perspective, multiple interesting studies have recently been published,^{24,26,29–31} including comparisons between two common commercial MS platforms.³² On the other hand, a large number of the applications of

nuclear magnetic resonance (NMR) spectroscopy in metabolomics have been spectroscopy-based chemometric approaches.^{5,33} Multiple highly implausible conclusions, for example in relation to coronary heart disease and cancer diagnostics, have been published.^{3,7} However, during the past 20 years NMR-based lipoprotein subclass profiling has been commercialized and become visible in epidemiology and clinical applications.^{34,35} NMR spectroscopy can also be used as a general method to quantify multiple molecular constituents in serum and in other biofluids.^{6,28,36–38} However, few applications apart from focused lipoprotein profiling,^{35,39} have been published in epidemiological contexts: only one quantitative serum metabolomics platform being systematically applied in metabolic profiling studies of more than a thousand people.^{6,28,40} The pros and cons of NMR and MS for metabolic profiling have been extensively covered in multiple reviews.^{2,6,41–44} MS-based lipidomics in epidemiology is reviewed in this issue by Meikle and co-workers,⁴⁵ with the anticipation that further progress is in sight from large, well-characterized cohorts. In addition, a compelling reminder of the current possibilities of *in vivo* metabolic phenotyping, and a vision of how to reach large-scale neurochemical profiling in epidemiological research, is provided in this issue by McKay and Tkáč.⁴⁶

Combining MS and NMR and notes on replication and causality

So far only a few epidemiological studies have combined MS and NMR methodologies. These are important for increasing the number of metabolic measures studied and also to validate biomarker findings by different technologies. Recently Wahl and colleagues⁴⁷ combined over 400 quantitative measures from serum MS and NMR platforms for over 1600 participants, when studying a multi-omic signature of body weight change in a population-based cohort. Würtz and colleagues¹⁵ corroborated NMR-based cardiovascular biomarker associations with MS in two population cohorts with 671 and 2289 individuals. In this issue, Vogt and coauthors⁴⁸ characterize associations between serum 25-hydroxyvitamin D concentrations and those of 415 metabolite and lipid measures, quantified by both NMR- and MS-based platforms in 1726 people from a population-based study, KORA F4. Importantly, they also replicated the majority of their findings in an independent population-based study with 6759 individuals for the NMR-based measures and 609 for the MS-based measures. In another study in this issue, Nelson and co-workers⁴⁹ also characterize associations between serum 25-hydroxyvitamin D and serum metabolites, using primarily a non-targeted MS-based approach with eventually

940 compounds identified in eight mutually exclusive chemical classes; lipids, amino acids, xenobiotics, peptides, co-factors and vitamins, carbohydrates, energy metabolites and nucleotides. This is a remarkable metabolic coverage from a technical point of view. Nevertheless, the results are weakened by the lack of replication. Comparison of the results from Nelson and co-workers⁴⁹ with those of Vogt and coauthors⁴⁸ illustrates the importance of biologically independent data; for example, the association of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) with 25-hydroxyvitamin D is similarly positive and strong in all three cohorts; however, eicosapentaenoate (EPA) and docosahexaenoate (DHA), which show strong positive associations in the ATBC study,⁴⁹ do not associate with 25-hydroxyvitamin D in KORA F4.⁴⁸ Possible explanation for this discrepancy is the finding in the ATBC study that retinol influenced the associations between 25-hydroxyvitamin D and EPA as well as DHA.⁴⁹

There are of course many possible confounding factors that complicate interpretations of cross-sectional epidemiological studies, particularly when aiming to infer causality,²² which Mendelian randomization analyses can attempt to circumvent. A recently published study, applying the Mendelian randomization framework^{50–53} to investigate potential causality in the association between 25-hydroxyvitamin D and schizophrenia, gives an exemplar of how, in certain cases, potential confounding by lifestyle factors can be minimized.⁵⁴ The study findings suggested that associations between schizophrenia and 25-hydroxyvitamin D may not be causal, and, therefore the evidential basis for vitamin D supplementation as a candidate approach for preventing schizophrenia is weakened. Similarly, a recent extensive Mendelian randomization study provides no support for a causal role for 25-hydroxyvitamin D in the risk of coronary artery disease.⁵⁵ On the other hand, in this issue Ong and co-workers⁵⁶ found that genetically lowered 25-hydroxyvitamin D levels were associated with higher susceptibility to ovarian cancer. Along the same lines, genetically lowered 25-hydroxyvitamin D levels have been found to be associated with increased susceptibility to multiple sclerosis.⁵⁷ Thus, in relation to these outcomes, vitamin D sufficiency may be important in delaying onset of or preventing the disease and might thus merit further investigations in long-term randomized controlled trials. These recent applications of the Mendelian randomization framework are interesting examples of causal epidemiology and a welcome reminder that observational association studies, such as those regarding 25-hydroxyvitamin D and circulating lipids and metabolites in this issue,^{48,49} are often prone to confounding and reverse causation.²² Furthermore, an important note here is that replication of observational

associations does not mean causation, as previously illustrated in the case of sex hormone-binding globulin and systemic metabolism.⁵⁸ In relation to these key challenges, also in this issue, Swerdlow and co-workers⁵⁹ present important guidance on how to plan and interpret Mendelian randomization studies on disease biomarkers: very relevant in the current era of a wealth of genetic data from genome-wide studies and the increasing number of quantitative metabolomics studies in epidemiology.

The use of Mendelian randomization analysis or randomized controlled trials to assess causality calls for certain prerequisites to be feasible.^{53,60,61} One interesting example in this issue is the study by Wang and co-workers⁶² on the effects of hormonal contraception on systemic metabolism. The difficulties in randomizing women to use hormonal contraception or placebo, and randomizing to hormonal or non-hormonal contraception, are obvious. Use of Mendelian randomization analysis to assess the causal effects of oestrogen and progesterone is currently limited by the lack of genetic variants that are reliable and consistent proxies for oestrogen and progesterone exposure. Furthermore, even were such variants to be identified, they might not mimic the effects of taking exogenous hormones. To address these difficulties and strengthen causal inference Wang *et al.*⁶² integrated findings from cross-sectional and longitudinal study settings. They assessed a comprehensive molecular profile of 75 metabolic measures and 37 cytokines in up to 5841 women within three population-based cohorts. Women using combined oral contraceptive pills (COCPs) were compared with those who did not use hormonal contraception. Metabolomics profiles were also reassessed for 869 women after 6 years to uncover the metabolic effects of starting, stopping and persistently using hormonal contraception. The extensive metabolic measurements allowed multiple novel findings on the systemic effects of COCPs. Perhaps of greater importance to public health, persistent use of COCPs did not appear to produce cumulative effects over time and the metabolic perturbations were reversed upon discontinuation.⁶²

The study by Wang and co-workers⁶² applied a quantitative serum NMR metabolomics platform; one that has commonly been used in epidemiology and genetics.^{6,40} The platform provides some 150 primary concentration measures. These include a fine-grained lipoprotein subclass profiling, and quantification of circulating fatty acids, amino acids, gluconeogenesis-related metabolites and many other molecules from multiple metabolic pathways, in addition to multiple biomarkers already routinely used in epidemiology.^{15–17,27,28,63–67} The primary measures can also be used to calculate many derived measures and metabolic ratios with potential biological importance. In addition to

the study by Wang and co-workers,⁶² three other papers in this issue also apply this methodology, namely the above-mentioned study on serum 25-hydroxyvitamin D by Vogt and co-authors⁴⁸ and two by Würtz and co-workers which look at metabolic profiling of alcohol consumption⁶⁸ and metabolic signatures of birthweight in adulthood.⁶⁹

Alcohol consumption in nearly 10 000 young adults (in a cross-sectional setting in three population-based cohorts) was associated with a complex metabolic signature, comprising both favourable and adverse effects in relation to the risk of cardiovascular disease and type 2 diabetes.⁶⁸ As in the study by Wang and co-workers,⁶² Würtz *et al.*⁶⁸ also complemented the cross-sectional study setting with a longitudinal set-up to be able to better assess the potential causality of the associations. In fact, the metabolic changes associated with the changes in alcohol intake (during 6-year follow-up in 1466 individuals) matched well with the cross-sectional results, increasing evidence that these changes were, at least partly, due to alcohol consumption. The results of Würtz *et al.*⁶⁸ can be interpreted along the lines of recent extensive Mendelian randomization analyses,⁷⁰ suggesting that reduction of alcohol consumption, even for light to moderate drinkers, is beneficial for cardiovascular health, with the obvious implication that Mendelian randomization studies of the influence of alcohol on the metabolome would be a natural extension of this work. The study looking at the metabolic signatures of birthweight in adulthood in 18 288 people is one the largest epidemiological metabolomics studies published to date.⁶⁹ These data show that lower birthweight is adversely associated with a wide range of established and emerging circulating cardiometabolic biomarkers in adulthood. However, the magnitudes of metabolic aberrations were weak (although statistically significant) and the authors questioned their public health relevance.⁶⁹ The pattern of metabolic deviations associated with lower birthweight resembled the metabolic signature of higher adult body mass index (R^2 0.77) with 1 kg lower birthweight being associated with similar metabolic aberrations as caused by 0.92 units higher body mass index in adulthood. The authors suggested that shared underlying metabolic pathways may be involved and concluded that birthweight is only a weak indicator of metabolic risk in adulthood.⁶⁹

Quantitative molecular data—the base for a multitude of statistical and clinical approaches

When metabolomics gets quantitative,^{5,6} it no longer matters if the technology is based on MS or NMR (or whatever methodology), the output just becomes a list of molecular

concentrations, the length and details of which depend on the method in question. This marks a fundamental distinction from diagnostics-oriented spectroscopy-based chemometric approaches; moving from (potentially thousands of) spectral data points to (typically up to a few hundred) identified molecular measures dramatically simplifies the statistical analyses and interpretations of epidemiological data. Of course, biological and clinical appreciation would need to be integrated into the metabolomics study rationale to change the search for non-existent binary disease states in the case of polygenic outcomes.^{5,6,9} Although the transformation from spectra to quantitative molecular measures is a challenge in itself, it is not discussed here since the topic falls into the domain of analytical chemistry and a plentiful literature is available.^{6,34,36,42,71–75} Nevertheless from the epidemiology perspective, with quantitative metabolomics data, i.e. with that list of molecular concentrations, all is back to basics and business as usual, apart from the fact that the list of molecular variables is longer than it has usually been in epidemiological studies. All standard statistical approaches can be applied in a straightforward manner, including adjustments for potential confounding factors.^{6,22,24,25,28} Of course, as with any quantitative molecular data, the analyses are by no means limited to standard approaches but, for example, multivariate non-linear approaches,^{76,77} network analyses,^{77,78} pathway approaches^{79,80} and integration of multi-omic data^{26,47,75,81–86} are all feasible. In fact, this is in contrast to spectral-based approaches in which these types of analyses, aiming for detailed biological understanding, would mostly be impossible to perform and interpret at the molecular level. Fearnley and Inouye,⁸⁷ in their review in this issue, survey epidemiological studies that leverage metabolomics and multi-omics to gain insight into disease mechanisms. Whereas they emphasize the role of quantitative metabolic data in biomarker identification and in understanding the metabolic underpinnings of diseases, they also underline limitations and discuss potential solutions in relation to statistical power issues with respect to sample sizes and limited coverage of relevant metabolites. They advocate a conceptual shift from metabolite concentrations towards experiments and graph-theoretical analyses based on the reactions themselves, and envision the identification of subgroups of individuals enriched for variation in relevant subregions of a reaction network in population-level epidemiological studies.⁸⁷

In another review in this issue, Sattar and colleagues discuss the applications and use of metabolomics in cardiometabolic intervention studies and trials.⁸⁸ They express their concerns regarding the small scale and focus on surrogate outcomes in most metabolomics studies in the area. Advancing a list of recommendations for future biomarker

studies, they call for multi-expertise research coalitions to work together for rigorous experimental study designs, with an early focus on truly relevant clinical questions:⁸⁸ the latter an issue recently elaborated in relation to clinical research in general by Ioannidis.⁸⁹ They also present an interesting and critical discussion on the potential role of metabolomics in predicting drug responses, and elaborate this in the case of statins. Their points are well made from the clinical point of view and very valuable to consider. Generally, the idea of individual metabolic phenotypes is alluring^{90–92} and might in some cases provide additional and predictive value, for not only drugs but dietary substances as well.^{41,93} However this does not necessarily translate into clinical relevance or applicability and, as the review by Sattar and colleagues⁸⁸ indicates, applications of metabolomics in clinical trials are scarce. Recently Würtz and co-workers published a proof-of-concept study¹⁷—a, “natural”, clinical trial of statin effects⁹⁴—in which they overcame the lack of metabolomics data in randomized controlled trials by using serially collected blood samples in population-based cohorts, in which a subset of individuals had started to use statins during follow-up. To verify that the observed metabolic changes were actually due to the effects of statins, the analyses were corroborated via Mendelian randomization analyses using a genetic variant in the *HMGCR* gene as an unconfounded proxy for the pharmacological action of statins. In fact, this type of combination of metabolomics data with genetic data in a large number of individuals readily extends to studies of all drugs with established genetic proxies mimicking their pharmacological action. With increasing numbers of extensive metabolomics and genetic data becoming available, we anticipate that comprehensive metabolic profiles of drug targets are likely to augment drug development in preclinical stages. Applications of two-sample Mendelian randomization would allow the gene-risk factor and gene-outcome associations to be taken from different data sources.⁹⁵

An early example in drug research is the Consortium for Metabonomic Toxicology, a collaboration that involved several pharmaceutical companies in applications of metabolomics to preclinical drug safety studies; this consortium, via the measurement of a dataset of NMR spectra of rodent urine and serum samples, built a predictive system for liver and kidney toxicity.⁹⁶ However, these approaches have not been widely adopted by the pharmaceutical industry. This reluctance was likely due to the fact that the methodologies originally used were spectroscopy-based and chemometrics-driven and thereby not sufficiently sensitive, quantitative, molecular-specific or platform-independent to permit routine or widespread implementation.⁹⁷ With the recent shift and developments in metabolomics towards quantitative molecular

methodologies,^{6,32} it may well be worthwhile to revisit this approach. In biomedical omics applications in general, it is also worth noting that there have been intensive developments regarding proteomics methods during the past few years, and their quantitative applications are likely soon to become feasible in large-scale studies to complement the information from other omics domains.^{98–100}

Commercial products and peer-reviewed publications

Intellectual property rights for most of the quantitative metabolomics platforms, particularly those applied in most epidemiological and clinical applications to date, are owned by companies.^{6,32} This is not surprising as such, since innovations are, manifestly, often developed by such enterprises. Ioannidis has recently reflected upon biomedical innovations and scientific peer review.^{89,101} He makes the point that 'stealth research' is prone to create ambiguity about what evidence can be trusted in a mix of (possibly) ground-breaking ideas, aggressive corporate announcements and mass media hype.⁸⁹ Even more recently, he has called for scientific peer-reviewed articles as a requirement for technologies aiming to affect health care at large.¹⁰¹ In this sense—of publishing peer-reviewed scientific articles—the current key metabolomics methodologies in epidemiology are reasonably represented.^{6,32} In fact, it appears that many companies operating in the metabolomics arena have made scientific peer-reviewed articles part of their business strategy. This is logical in light of the great potential for commercial benefit provided by independent technological validation by the scientific community. This is something that cannot be achieved by patents or intellectual property rights alone; high-quality peer-reviewed publications are hard to copy or buy. However what still partly remains, even in the peer-reviewed scientific literature, is ungrounded hype and expectations of omics sciences transforming not only biological knowledge, but also medicine and public health.¹⁰² In relation to clinical applications, we should also keep in mind the problematic pathway from the announcement of new biomarkers to their integration into predictive and diagnostic models or validated target identification.^{18,20,103–107}

Is the future for metabolic phenotyping in epidemiology precarious?

In the history of science and medicine, remarkable leaps in progress have often been made due to novel physical or chemical technologies. The new omics methodologies have already taken a big step, particularly in combination with genomic data, but also generally in biomedical sciences.

Quantitative molecular technologies have been developed, many of which are ready for integration into large-scale epidemiological studies. There is much interest in 'multi-omic' science, in addition to epidemiological and potential clinical applications. However, considerable hype has also been generated, often in connection with the concept of personalized or precision medicine and clinical diagnostic applications. We suggest that for the future meaningful development of metabolic phenotyping in epidemiological and (potentially) clinical settings, much of the early metabolomics literature should be put behind us, just as we needed to discard a large (and largely meaningless) 'candidate gene' literature with the arrival of genome-wide association studies.¹⁰⁸ We should embrace some of the basic requirements of good molecular epidemiology: molecular identification and quantification, large-scale studies, independent biological replication of results, and an appreciation of confounding with the aim of understanding causation. We should combine different metabolomics methodologies and multiomics combinations to triangulate findings, explore multiple angles and put findings into a biological perspective. Furthermore we should apply appropriate statistical tools (noting caveats related to multiple testing) and, maybe most importantly, apply self-critical interpretation of statistical results, biological implications and potential clinical applicability. Last, we should carefully reflect—against all the hopes and hypes of personalized medicine—on the fundamentals of biological processes in polygenic conditions, and the epidemiological connotations of this with respect to the articulation of population and individual perspectives.^{10,11} As demonstrated by many excellent contributions in this themed issue, large-scale metabolic phenotyping, together with many other omics technologies, are already here to enrich epidemiology and eventually to make irreversible headway in the era of systems epidemiology.

Funding

MAK has received funding from the Sigrid Juselius Foundation and strategic research funding from the University of Oulu, Finland. MAK and GDS work in a Unit that receives funds from the University of Bristol and UK Medical Research Council (MC_UU_12013/1). The funders had no role in study design, decision to publish, or preparation of the manuscript.

References

1. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. *Xenobiotica* 1999;29: 1181–89.

2. Dunn WB, Broadhurst DI, Atherton HJ, Goodacre R, Griffin JL. Systems level studies of mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. *Chem Soc Rev* 2011;**40**:387–426.
3. Ala-Korpela M. Potential role of body fluid ¹H NMR metabolomics as a prognostic and diagnostic tool. *Expert Rev Mol Diagn* 2007;**7**:761–73.
4. Ala-Korpela M. Critical evaluation of ¹H NMR metabolomics of serum as a methodology for disease risk assessment and diagnostics. *Clin Chem Lab Med* 2008;**46**:27–42.
5. Ala-Korpela M, Kangas AJ, Soininen P. Quantitative high-throughput metabolomics: a new era in epidemiology and genetics. *Genome Med* 2012;**4**:36.
6. Soininen P, Kangas AJ, Würtz P, Suna T, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. *Circ Cardiovasc Genet* 2015;**8**:192–206.
7. Ala-Korpela M. Metabolomics in cardiovascular medicine: Not personalised, not diagnostic. *Eur J Prev Cardiol* 2016 [epub ahead of print]. doi: 10.1177/2047487316664443.
8. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. *Metabolomics* 2013;**9**:280–99.
9. Madsen R, Lundstedt T, Trygg J. Chemometrics in metabolomics - a review in human disease diagnosis. *Anal Chim Acta* 2010;**659**:23–33.
10. Rose G. Sick individuals and sick populations. *Int J Epidemiol* 1985;**14**:32–38.
11. Davey Smith G. Epidemiology, epigenetics and the ‘Gloomy Prospect’: embracing randomness in population health research and practice. *Int J Epidemiol* 2011;**40**:537–62.
12. Hey SP, Kesselheim AS. Countering imprecision in precision medicine. *Science* 2016;**353**:448–49.
13. Davey Smith G, Relton CL, Brennan P. Chance, choice and cause in cancer aetiology: individual and population perspectives. *Int J Epidemiol* 2016;**45**:605–13.
14. Plomin R, Haworth CMA, Davis OSP. Common disorders are quantitative traits. *Nat Rev Genet* 2009;**10**:872–78.
15. Würtz P, Havulinna AS, Soininen P *et al*. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. *Circulation* 2015;**131**:774–85.
16. Würtz P, Mäkinen V-P, Soininen P *et al*. Metabolic signatures of insulin resistance in 7,098 young adults. *Diabetes* 2012;**61**:1372–80.
17. Würtz P, Wang Q, Soininen P *et al*. Metabolomic profiling of statin use and genetic inhibition of HMG-CoA reductase. *J Am Coll Cardiol* 2016;**67**:1200–10.
18. Ware JH. The limitations of risk factors as prognostic tools. *N Engl J Med* 2006;**355**:2615–17.
19. Wang TJ. Assessing the role of circulating, genetic, and imaging biomarkers in cardiovascular risk prediction. *Circulation* 2011;**123**:551–65.
20. Niiranen TJ, Vasana RS. Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. *Exp Rev Cardiovasc Ther* 2016;**14**:855–69.
21. Robinson EB, Pourcain BS, Anttila V *et al*. Genetic risk for autism spectrum disorders and neuropsychiatric variation in the general population. *Nat Genet* 2016;**48**:552–55.
22. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Day I, Ebrahim S. Clustered environments and randomized genes: a fundamental distinction between conventional and genetic epidemiology. *PLoS Med* 2007;**4**:e352.
23. Baig F, Pechlaner R, Mayr M. Caveats of untargeted metabolomics for biomarker discovery. *J Am Coll Cardiol* 2016;**68**:1294–96.
24. Suhre K, Shin S-Y, Petersen A-K *et al*. Human metabolic individuality in biomedical and pharmaceutical research. *Nature* 2011;**477**:54–60.
25. Suhre K, Wallaschofski H, Raffler J *et al*. A genome-wide association study of metabolic traits in human urine. *Nat Genet* 2011;**43**:565–69.
26. Suhre K, Raffler J, Kastenmüller G. Biochemical insights from population studies with genetics and metabolomics. *Arch Biochem Biophys* 2016;**589**:168–76.
27. Kettunen J, Tukiainen T, Sarin A-P *et al*. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. *Nat Genet* 2012;**44**:269–76.
28. Kettunen J, Demirkan A, Würtz P *et al*. Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA. *Nat Commun* 2016;**7**:11122.
29. Shin S-Y, Fauman EB, Petersen A-K *et al*. An atlas of genetic influences on human blood metabolites. *Nat Genet* 2014;**46**:543–50.
30. Menni C, Kastenmüller G, Petersen A-K *et al*. Metabolomic markers reveal novel pathways of ageing and early development in human populations. *Int J Epidemiol* 2013;**42**:1111–19.
31. Wang TJ, Larson MG, Vasana RS *et al*. Metabolite profiles and the risk of developing diabetes. *Nat Med* 2011;**17**:448–53.
32. Yet I, Menni C, Shin S-Y *et al*. Genetic influences on metabolite levels: a comparison across metabolomic platforms. *PLoS One* 2016;**11**:e0153672.
33. Dona AC, Coffey S, Figtree G. Translational and emerging clinical applications of metabolomics in cardiovascular disease diagnosis and treatment. *Eur J Prev Cardiol* 2016 [epub ahead of print]. doi: 10.1177/2047487316645469.
34. Ala-Korpela M. ¹H NMR spectroscopy of human blood plasma. *Prog Nucl Magn Reson Spectrosc* 1995;**27**:475–554.
35. Mallol R, Rodriguez MA, Brezmes J, Masana L, Correig X. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. *Prog Nucl Magn Reson Spectrosc* 2013;**70**:1–24.
36. Mierisová S, Ala-Korpela M. MR spectroscopy quantitation: a review of frequency domain methods. *NMR Biomed* 2001;**14**:247–59.
37. Dona AC, Jimenez B, Schäfer H *et al*. Precision high-throughput proton NMR spectroscopy of human urine, serum and plasma for large-scale metabolic phenotyping. *Anal Chem* 2014;**86**:9887–94.
38. Demirkan A, Henneman P, Verhoeven A *et al*. Insight in genome-wide association of metabolite quantitative traits by exome sequence analyses. *PLoS Genet* 2015;**11**:e1004835.
39. Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. *Circulation* 2014;**129**:553–61.
40. Soininen P, Kangas AJ, Würtz P *et al*. High-throughput serum NMR metabolomics for cost-effective holistic studies on systemic metabolism. *Analyst* 2009;**134**:1781–85.

41. van Duynhoven JPM, Jacobs DM. Assessment of dietary exposure and effect in humans: the role of NMR. *Prog Nucl Magn Reson Spectrosc* 2016;**96**:58–72.
42. Lind MV, Savolainen OI, Ross AB. The use of mass spectrometry for analysing metabolite biomarkers in epidemiology: methodological and statistical considerations for application to large numbers of biological samples. *Eur J Epidemiol* 2016;**31**: 717–33.
43. Quehenberger O, Dennis EA. The human plasma lipidome. *N Engl J Med* 2011;**365**:1812–23.
44. Rankin NJ, Preiss D, Welsh P *et al.* The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective. *Atherosclerosis* 2014;**237**:287–300.
45. Mundra PA, Shaw JE, Meikle PJ. Lipidomic analyses in epidemiology. *Int J Epidemiol* 2016;**45**:1329–38.
46. McKay J, Tkáč I. Quantitative in vivo neurochemical profiling in humans: where are we now? *Int J Epidemiol* 2016;**45**: 1339–50.
47. Wahl S, Vogt S, Stückler F *et al.* Multi-omic signature of body weight change: results from a population-based cohort study. *BMC Med* 2015;**13**:48.
48. Vogt S, Wahl S, Kettunen J *et al.* Characterization of the metabolic profile associated with serum 25-hydroxyvitamin D: a cross-sectional analysis in population-based data. *Int J Epidemiol* 2016;**45**:1469–81.
49. Nelson SM, Panagiotou OA, Anic GM *et al.* Metabolomics analysis of serum 25-hydroxy-vitamin D in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. *Int J Epidemiol* 2016;**45**:1458–68.
50. Davey Smith G, Ebrahim S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? *Int J Epidemiol* 2003;**32**:1–22.
51. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. *Hum Mol Genet* 2014;**23**:R89–98.
52. Burgess S, Timpson NJ, Ebrahim S, Davey Smith G. Mendelian randomization: where are we now and where are we going? *Int J Epidemiol* 2015;**44**:379–88.
53. Haycock PC, Burgess S, Wade KH, Bowden J, Relton C, Davey Smith G. Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am J Clin Nutr* 2016;**103**:965–78.
54. Taylor AE, Burgess S, Ware JJ *et al.* Investigating causality in the association between 25(OH)D and schizophrenia. *Sci Rep* 2016;**6**:26496.
55. Manousaki D, Mokry LE, Ross S, Goltzman D, Richards JB. Mendelian randomization studies do not support a role for vitamin D in coronary artery disease. *Circ Cardiovasc Genet* 2016;**9**:349–56.
56. Ong JS, Cuellar-Partida G, Lu Y *et al.* Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. *Int J Epidemiol* 2016;**45**:1619–30.
57. Mokry LE, Ross S, Ahmad OS *et al.* Vitamin D and risk of multiple sclerosis: a Mendelian randomization study. *PLoS Med* 2015;**12**:e1001866.
58. Wang Q, Kangas AJ, Soyninen P *et al.* Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates. *Int J Epidemiol* 2015;**44**:623–37.
59. Swerdlow DI, Kuchenbaecker KB, Shah S *et al.* Selecting instruments for Mendelian randomization in the wake of genome-wide association studies. *Int J Epidemiol* 2016;**45**:1600–16.
60. Evans DM, Davey Smith G. Mendelian randomization: new applications in the coming age of hypothesis-free causality. *Annu Rev Genomics Hum Genet* 2015;**16**:327–50.
61. Collins R, Reith C, Emberson J *et al.* Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016 [epub ahead of print]. doi: 10.1016/S0140-6736(16)31357-5.
62. Wang Q, Würtz P, Auro K *et al.* Effects of hormonal contraception on systemic metabolism: cross-sectional and longitudinal evidence. *Int J Epidemiol* 2016;**45**:1445–57.
63. Würtz P, Kangas AJ, Soyninen P *et al.* Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: a note on Mendelian randomization studies. *J Am Coll Cardiol* 2013;**62**: 1906–08.
64. Würtz P, Wang Q, Kangas AJ *et al.* Metabolic signatures of adiposity in young adults: Mendelian randomization analysis and effects of weight change. *PLoS Med* 2014;**11**:e1001765.
65. Fischer K, Kettunen J, Würtz P *et al.* Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. *PLoS Med* 2014;**11**:e1001606.
66. Auro K, Joensuu A, Fischer K *et al.* A metabolic view on menopause and ageing. *Nat Commun* 2014;**5**:4708.
67. Kujala UM, Mäkinen V-P, Heinonen I *et al.* Long-term leisure-time physical activity and serum metabolome. *Circulation* 2013;**127**:340–48.
68. Würtz P, Cook S, Wang Q *et al.* Metabolic profiling of alcohol consumption in 9778 young adults. *Int J Epidemiol* 2016;**45**:1493–506.
69. Würtz P, Wang Q, Niironen M *et al.* Metabolic signatures of birthweight in 18 288 adolescents and adults. *Int J Epidemiol* 2016;**45**:1539–50.
70. Holmes MV, Dale CE, Zuccolo L *et al.* Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. *BMJ* 2014; **349**:g4164.
71. Mihaleva VV, van Schalkwijk DB, de Graaf AA *et al.* A systematic approach to obtain validated partial least square models for predicting lipoprotein subclasses from serum NMR spectra. *Anal Chem* 2014;**86**:543–50.
72. Mihaleva VV, Korhonen S-P, van Duynhoven J, Niemitz M, Vervoort J, Jacobs DM. Automated quantum mechanical total line shape fitting model for quantitative NMR-based profiling of human serum metabolites. *Anal Bioanal Chem* 2014; **406**:3091–102.
73. Alonso A, Marsal S, Julià A. Analytical methods in untargeted metabolomics: state of the art in 2015. *Front Bioeng Biotechnol* 2015;**3**:1514.
74. Vehtari A, Mäkinen V-P, Soyninen P *et al.* A novel Bayesian approach to quantify clinical variables and to determine their spectroscopic counterparts in ¹H NMR metabolomic data. *BMC Bioinformatics* 2007;**8**(Suppl 2):S8.

75. Inouye M, Kettunen J, Soininen P *et al.* Metabonomic, transcriptomic, and genomic variation of a population cohort. *Mol Syst Biol* 2010;**6**:441.
76. Mäkinen V-P, Soininen P, Kangas AJ *et al.* Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. *J Intern Med* 2013;**273**:383–95.
77. Mäkinen V-P, Tynkkynen T, Soininen P *et al.* Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). *J Proteome Res* 2012;**11**:1782–90.
78. Mäkinen V-P, Forsblom C, Thorn LM *et al.* Network of vascular diseases, death and biochemical characteristics in a set of 4,197 patients with type 1 diabetes (the FinnDiane Study). *Cardiovasc Diabetol* 2009;**8**:54.
79. Krumsiek J, Suhre K, Illig T, Adamski J, Theis FJ. Gaussian graphical modeling reconstructs pathway reactions from high-throughput metabolomics data. *BMC Syst Biol* 2011;**5**:21.
80. Krumsiek J, Mittelstrass K, Do KT *et al.* Gender-specific pathway differences in the human serum metabolome. *Metabolomics* 2015;**11**:1815–33.
81. Inouye M, Ripatti S, Kettunen J *et al.* Novel loci for metabolic networks and multi-tissue expression studies reveal genes for atherosclerosis. *PLoS Genet* 2012;**8**:e1002907.
82. Ala-Korpela M, Kangas AJ, Inouye M. Genome-wide association studies and systems biology: together at last. *Trends Genet* 2011;**27**:493–98.
83. Ritchie SC, Würtz P, Nath AP *et al.* The biomarker GlycA is associated with chronic inflammation and predicts long-term risk of severe infection. *Cell Systems* 2015;**1**:293–301.
84. Petersen A-K, Zeilinger S, Kastenmüller G *et al.* Epigenetics meets metabolomics: an epigenome-wide association study with blood serum metabolic traits. *Hum Mol Genet* 2014;**23**:534–45.
85. Krumsiek J, Bartel J, Theis FJ. Computational approaches for systems metabolomics. *Curr Opin Biotechnol* 2016;**39**:198–206.
86. Kastenmüller G, Raffler J, Gieger C, Suhre K. Genetics of human metabolism: an update. *Hum Mol Genet* 2015;**24**:R93–R101.
87. Fearnley LG, Inouye M. Metabolomics in epidemiology: from metabolite concentrations to integrative reaction networks. *Int J Epidemiol* 2016;**45**:1319–28.
88. Rankin NJ, Preiss D, Welsh P, Sattar N. Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future. *Int J Epidemiol* 2016;**45**:1351–71.
89. Ioannidis JPA. Why most clinical research is not useful. *PLoS Med* 2016;**13**:e1002049.
90. Clayton TA, Lindon JC, Cloarec O *et al.* Pharmaco-metabonomic phenotyping and personalized drug treatment. *Nature* 2006;**440**:1073–77.
91. Assfalg M, Bertini I, Colangiuli D *et al.* Evidence of different metabolic phenotypes in humans. *Proc Natl Acad Sci U S A* 2008;**105**:1420–24.
92. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. *Proc Natl Acad Sci U S A* 2009;**106**:14728–33.
93. Larmo PS, Kangas AJ, Soininen P *et al.* Effects of sea buckthorn and bilberry on serum metabolites differ according to baseline metabolic profiles in overweight women: a randomized cross-over trial. *Am J Clin Nutr* 2013;**98**:941–51.
94. Voora D, Shah SH. Pharmacometabolomics meets genetics. *J Am Coll Cardiol* 2016;**67**:1211–13.
95. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG; EPIC-InterAct Consortium. Using published data in Mendelian randomization: a blueprint for efficient identification of causal risk factors. *Eur J Epidemiol* 2015;**30**:543–52.
96. Lindon JC, Holmes E, Nicholson JK. Metabonomics in pharmaceutical RandD. *FEBS J* 2007;**274**:1140–51.
97. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. *Nat Rev Drug Discov* 2016;**15**:473–84.
98. Hathout Y. Proteomic methods for biomarker discovery and validation. Are we there yet? *Exp Rev Proteomics* 2015;**12**:329–31.
99. Williams EG, Wu Y, Jha P *et al.* Systems proteomics of liver mitochondria function. *Science* 2016;**352**:aad0189.
100. Billing AM, Ben Hamidane H, Bhagwat AM *et al.* Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells. *J Proteomics* 2017;**150**:86–97.
101. Ioannidis JPA. Stealth research and Theranos: reflections and update 1 year later. *JAMA* 2016;**316**:389–90.
102. Ioannidis JPA. Expectations, validity, and reality in omics. *J Clin Epidemiol* 2010;**63**:945–49.
103. Rockhill B, Kawachi I, Colditz GA. Individual risk prediction and population-wide disease prevention. *Epidemiol Rev* 2000;**22**:176–80.
104. Poste G. Bring on the biomarkers. *Nature* 2011;**469**:156–57.
105. Ioannidis JPA, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. *Circ Res* 2012;**110**:658–62.
106. Moons KGM, Altman DG, Reitsma JB *et al.* Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. *Ann Intern Med* 2015;**162**:W1–73.
107. Vargas AJ, Harris CC. Biomarker development in the precision medicine era: lung cancer as a case study. *Nat Rev Cancer* 2016;**16**:525–37.
108. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. *Lancet* 2003;**361**:865–72.